Stay informed about the latest diabetes news and research, including medical discoveries, treatment developments, clinical studies, technology and emerging health insights.
A new analysis suggests that the effectiveness of GLP-1 receptor mono-agonists in obesity treatment varies significantly with drug type and dosage, underscoring the importance of personalised therapy for improved cardiometabolic outcomes. A new analysis of GLP-1 medicines suggests that both…
Aqua Medical has appointed Robert “Bob” Haggerty as its new chief executive to advance the development of its minimally invasive PIMA procedure, currently in early-stage testing for potential use against type 2 diabetes. Aqua Medical has named Robert “Bob” Haggerty…
Rajasthan has expanded its Mission Madhuhari diabetes programme by integrating artificial intelligence and digital tools, aiming to improve early detection, patient follow-up, and long-term outcomes, especially in rural and underserved communities. Rajasthan has widened its Mission Madhuhari diabetes programme by…
Eli Lilly’s rapid growth driven by GLP-1 drugs faces scrutiny as the company prepares for new product launches amid high valuations, with investors keenly awaiting Q2 results for further signals of sustained momentum. Eli Lilly may have delivered only modest…
Despite their medical breakthroughs, GLP-1 medicines like Wegovy and Zepbound face social resistance, revealing enduring biases that judge weight loss by medication as morally inferior to lifestyle change, potentially undermining health outcomes. GLP-1 medicines were supposed to mark a cultural…
While intermittent fasting continues to gain popularity for its potential health benefits, experts warn that it is not suitable for everyone and caution against oversimplified claims, emphasising the importance of personalised approaches and professional guidance. Il digiuno intermittente has become…
A new smart ring developed by UC San Diego researchers can continuously track multiple chemical signals in sweat, offering a potential breakthrough in non-invasive health monitoring, especially for diabetes management. Researchers at the University of California San Diego have developed…
A patient-developed open-source app linked to glucose monitoring devices delivers better control for type 1 diabetics than traditional FDA-approved tools, highlighting the need for regulatory reform to keep up with rapid technological innovation. For people with type 1 diabetes, the…
Emerging supplements like Elcella and Calocurb claim to promote natural satiety and reduce cravings by stimulating the body’s own hunger hormones, offering a potential alternative to injectable diabetes medications amid cautious scientific optimism. Natural weight-management products are being promoted as…
Dexcom’s latest quarter highlights a 13% revenue rise driven by clinical advances and FDA clearance for paediatric use, as the company aims to outpace rivals in a crowded CGM market, despite operational challenges. Dexcom’s latest quarter gave investors several reasons…
The US FDA has selected Dexcom for its pioneering TEMPO programme, enabling digital health products to reach patients while gathering real-world performance data, marking a significant change in regulatory approach. The US Food and Drug Administration has picked Dexcom as…
Biocon Biologics has begun selling Yesafili in the US, marking its first entry into the American ophthalmology market with an interchangeable biosimilar to Regeneron’s Eylea, following FDA approval and a settlement with the US company. Biocon Biologics has begun selling…
